The expansion of Lantern Pharma's Harmonic clinical trial into new markets like Japan and Taiwan not only signifies regulatory success but also opens up larger demographic pools for its non-small cell lung cancer treatment in never-smokers. This development is likely to be viewed positively by investors, as it represents progress in the company's pipeline and potential for future revenue growth. The immediate positive reaction in stock price reflects market optimism about the company's growth trajectory and its ability to navigate regulatory landscapes in significant markets.